Emily Su

ORCID: 0000-0003-4527-8527
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Genomics and Diagnostics
  • Microtubule and mitosis dynamics
  • Cell Image Analysis Techniques
  • 3D Printing in Biomedical Research
  • Radiomics and Machine Learning in Medical Imaging
  • PARP inhibition in cancer therapy

Dana-Farber Cancer Institute
2019-2020

Reproductive Science Center
2012

National Institute of Environmental Health Sciences
2012

Eunice Kennedy Shriver National Institute of Child Health and Human Development
2012

National Institutes of Health
2012

Center for Scientific Review
2012

Eisenhower Medical Center
2012

Ottawa Hospital
2012

Ottawa Hospital Research Institute
2012

Despite decades of effort, the sensitivity patient tumors to individual drugs is often not predictable on basis molecular markers alone. Therefore, unbiased, high-throughput approaches match effective drugs, without requiring a priori hypotheses, are critically needed. Here, we improved upon method that previously reported and developed called dynamic BH3 profiling (HT-DBP). HT-DBP microscopy-based, single-cell resolution assay enables chemical screens hundreds thousands candidate freshly...

10.1126/scisignal.aay1451 article EN Science Signaling 2020-06-16

Abstract Phenotypic differences between primary patient tumors and models of that are amenable to chemical screening represents a key barrier drug discovery repurposing. High-throughput technologies can accurately identify active drugs using therefore valuable additions the development toolbox may have direct clinical utility as predictive biomarkers. Here we report method called high-throughput dynamic BH3 profiling (HT-DBP), robust microscopy-based assay with single-cell resolution enables...

10.1158/1538-7445.am2019-4478 article EN Cancer Research 2019-07-01

Phenotypic differences between primary patient tumors and models of that are amenable to chemical screening represents a key barrier drug discovery repurposing. High-throughput technologies can accurately identify active drugs using therefore valuable additions the development toolbox may have direct clinical utility as predictive biomarkers. Here we report method called high-throughput dynamic BH3 profiling (HT-DBP), robust microscopy-based assay with single-cell resolution enables screens...

10.1158/1538-7445.sabcs18-4478 article EN Experimental and Molecular Therapeutics 2019-07-01
Coming Soon ...